Efficacy and safety of azithromycin combined with montelukast sodium and mometasone furoate nasal spray in the treatment of upper airway cough syndrome caused by allergic rhinitis in children
Objective To analyze the efficacy and safety of azithromycin combined with montelukast sodium and mometasone furoate nasal spray in the treatment of upper airway cough syndrome(UACS)caused by allergic rhinitis(AR)in children.Methods From January 2020 to December 2022,86 children with UACS caused by AR were selected as the research objects.According to the difference of treatment plan,the children were divided into control group(43 cases,montelukast sodium + mometasone furoate nasal spray)and study group(43 cases,azithromycin + montelukast sodium + mometasone furoate nasal spray).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the cough score and Face,Legs,Activity,Cry,Consolability Behavioral Tool(FLACC)score of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,the fractional exhaled nitric oxide(FENO),tumor necrosis factor-α(TNF-α)levels and T helper cell 2(Th2)of the study group were lower than those of the control group,and the T helper cell 1(Th1)and Th1/Th2 were higher than those of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Azithromycin combined with montelukast sodium and mometasone furoate nasal spray in the treatment of UACS caused by AR can improve the cough symptoms of children,regulate clinical indicators,improve the overall clinical efficacy,with high safety and high application value.
万方数据
维普
